Cytochrome P450 enzyme mutant and application thereof in catalyzing glycyrrhetinic acid
By mutation of amino acids at specific sites of cytochrome P450 enzyme, an enzyme mutant that can efficiently selectively catalyze the formation of 7β-hydroxyglycerol in glycyrrhizic acid, solving the problem of inert C-H bond activation and insufficient selectivity in traditional methods. , achieving efficient and economical modification of licorice.
Patent Information
- Application Number
- CN202411457830.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-18
- Publication Date
- 2024-11-29
AI Technical Summary
Traditional organic synthesis methods are difficult to efficiently selectively activate the inert C-H bonds in glycyrrhizic acid, and the existing cytochrome P450 enzyme has poor regio-selectivity when catalyzing glycyrrhizic acid, which increases the difficulty of separation and purification.
By mutating the amino acid sequence of the cytochrome P450 enzyme at a specific site, the mutant is constructed to improve its catalytic selectivity and yield of 7β-hydroxylation of glycyrrhizic acid, including mutations at amino acids 288-291, For example, threonine becomes alanine, valine, glycine, etc., forming an excellent selectivity and high yield catalytic system.
The high selectivity and high yield of 7β-hydroxyglycerol in the production of glycyrrhizic acid are achieved, the separation operation in the process is simplified, the production cost is reduced, and the structural modification of glycyrrhizic acid is provided is provided more effective tools.
Smart Images

Figure CN119040287A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a cytochrome P450 enzyme mutant and application thereof in catalyzing glycyrrhetinic acid, belonging to the field of mutants. Background Art
[0002] Glycyrrhetinic acid is a common pentacyclic triterpenoid natural product. Currently, chemical modification of its C3-OH, C30-COOH and unsaturated enone sites has successfully obtained a variety of glycyrrhetinic acid derivatives with a wide range of pharmacological activities such as anti-tumor, anti-inflammatory, and antioxidant. However, due to the large number of inert CH bonds in the structure of glycyrrhetinic acid, traditional organic synthesis methods are difficult to achieve efficient and selective activation of inert CH bonds, and the chemical space needs to be further developed.
[0003] Cytochrome P450 enzymes can efficiently and selectively oxidize a variety of complex natural products under mild conditions, showing significant advantages of green environmental protection and efficient catalysis, especially in the selective activation of inert CH bonds. The catalysis of cytochrome P450 enzymes depends on the generation of highly active intermediate I, which achieves selective activation of substrate inert CH bonds through the synergistic effect of the heme center and the enzyme active cavity. The cytochrome P450 enzyme ApPT isolated from the actinomycete Amycolatopsis pretoriensis can be used for the selective activation of inert CH bonds of glycyrrhetinic acid. However, in this reaction process, in addition to the generation of 7β-hydroxyglycyrrhetinic acid product, 7β, 15α-dihydroxyglycyrrhetinic acid product is also generated at the same time, which has poor regioselectivity and increases the difficulty of separation and purification.
[0004] In view of this, the active cavity of ApPT was modified for the regioselective hydroxylation of glycyrrhetinic acid to produce 7β-hydroxyglycyrrhetinic acid, which improved the catalytic selectivity, simplified the separation operation in the process, facilitated engineering implementation, and provided a more effective tool for the structural modification of glycyrrhetinic acid. Summary of the invention
[0005] Purpose of the invention: The technical problem to be solved by the present invention is to provide a cytochrome P450 enzyme mutant and its application in catalyzing glycyrrhetinic acid; the cytochrome P450 enzyme mutant can catalyze glycyrrhetinic acid to produce 7β-hydroxyglycyrrhetinic acid with excellent selectivity and / or high yield.
[0006] Technical solution: In order to solve the above technical problems, the present invention provides a cytochrome P450 enzyme mutant, wherein the mutation site of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT as shown in SEQ ID NO.1 is any one or several of positions 288-291; the amino acid at position 288 mutates from threonine to alanine, valine or glycine; the amino acid at position 289 mutates from serine to glutamine; the amino acid at position 290 mutates from glycine to glutamate; the amino acid at position 291 mutates from threonine to alanine, valine, serine, phenylalanine, isoleucine, leucine or cysteine.
[0007] Among them, the mutation site of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT shown in SEQ ID NO.1 is position 291; the amino acid at position 291 mutates from threonine to alanine, valine, serine, phenylalanine, isoleucine, leucine or cysteine.
[0008] The mutation site of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT as shown in SEQ ID NO.1 is position 288; the amino acid at position 288 is mutated from threonine to alanine or valine.
[0009] Among them, the mutation sites of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT shown in SEQ ID NO.1 are positions 291 and 288; the amino acid at position 291 mutates from threonine to isoleucine; and the amino acid at position 288 mutates from threonine to alanine or glycine.
[0010] Among them, the mutation sites of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT shown in SEQ ID NO.1 are position 291 and position 288-289; the amino acid at position 291 mutates from threonine to isoleucine; the amino acid at position 288 mutates from threonine to glycine; and the amino acid at position 289 mutates from serine to glutamine.
[0011] Among them, the mutation sites of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT shown in SEQ ID NO.1 are position 291, position 288 and position 290; the amino acid at position 291 mutates from threonine to isoleucine; the amino acid at position 288 mutates from threonine to alanine; and the amino acid at position 290 mutates from glycine to glutamate.
[0012] Among them, the mutation sites of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT shown in SEQ ID NO.1 are positions 288-291; the amino acid at position 291 mutates from threonine to isoleucine; the amino acid at position 288 mutates from threonine to alanine or glycine; the amino acid at position 289 mutates from serine to glutamine; and the amino acid at position 290 mutates from glycine to glutamate.
[0013] The cytochrome P450 enzyme gene CYP161H12 of the present invention (now named as ApPT gene) is derived from actinomycete Amycolatopsis pretoriensis, the amino acid sequence UniProt number is A0A1H5RFX8, the amino acid sequence (404aa) of the encoded protein is shown in the sequence table SEQ ID NO: 1, and the nucleotide sequence (1212bp) is shown in the sequence table SEQ ID NO: 2. The gene of the enzyme is directly synthesized by General Bio (Anhui) Co., Ltd. onto the pET28a-RHFRed vector to obtain the pET28a-ApPT-RHFRed recombinant plasmid. The pET28a-ApPT-RHFRed recombinant plasmid was transformed into E. coli BL21 competent cells by heat shock method, and positive transformants were screened on LB solid medium (containing 50 μg / mL kanamycin); a single clone was picked into 5 mL of sterile LB liquid medium (containing 50 μg / mL kanamycin), and cultured at 37°C, 220 rpm for 10 h to obtain the pET28a-ApPT-RHFRed recombinant bacterial solution. The specific implementation method is shown in Example 1.
[0014] Using pET28a-ApPT-RHFRed plasmid as a template, design mutation primers, place the base to be mutated in the middle of the primer, clone the mutated gene by PCR, mix the linearized vector and the gene cloned by PCR in proportion, connect them together under the action of homologous recombinase, transform them into E.coli DH5α competent cells, and screen positive transformants on LB solid medium (containing 50μg / mL kanamycin). Pick a single clone colony to 5mL LB liquid medium containing 50μg / mL kanamycin for culture, and then sequence it. Use Snap Gene software to compare the sequencing results with the gene sequence of wild-type ApPT, and extract the plasmid from the strain with correct sequencing. The cytochrome P450 enzyme mutant recombinant plasmid was transformed into E. coli BL21 competent cells by heat shock method, and positive transformants were screened on LB solid medium (containing 50 μg / mL kanamycin); a single clone was picked and added to 5 mL of sterile LB liquid medium (containing 50 μg / mL kanamycin), and cultured at 37°C and 220 rpm for 10 h to obtain a cytochrome P450 enzyme mutant recombinant bacterial liquid. The specific implementation method is shown in Example 2.
[0015] Heterologous expression of cytochrome P450 enzymes in E. coli: Add cytochrome P450 parent template and mutant enzyme recombinant bacterial solution to 50 ml sterilized TB medium at a 0.3%-0.5% inoculum, and add 50 μg / mL kanamycin and 1 mL / L trace metal salt solution. Cultivate at 37°C, 220 rpm until OD 600 The value is 0.6-0.8. After cooling in an ice water bath for 20 minutes, 0.1 mM isopropyl-β-D-thiogalactoside (IPTG) and 0.5 mM 5-aminolevulinic acid hydrochloride (5-ALA) are added thereto to induce the bacteria to express cytochrome P450 protein, and the induction culture is carried out at 18°C and 200 rpm for 20 hours. The bacteria are collected by centrifugation at 3750 rpm for 15 minutes. The specific implementation method is shown in Examples 1 and 2.
[0016] Heterologous expression of opt13 in E. coli: Use seamless cloning technology to connect opt13 and vector pRSFDuet to obtain the recombinant plasmid pRSFDuet-opt13, which is then transformed into E. coli BL21. Add the above recombinant bacterial solution to 50 ml sterilized TB medium at a 0.3%-0.5% inoculum, and add 50 μg / mL kanamycin. Cultivate at 37°C, 220 rpm until OD 600The value is 0.6-0.8. After cooling in an ice water bath for 20 minutes, 0.1 mM isopropyl-β-D-thiogalactoside (IPTG) is added thereto to induce the bacteria to express protein opt13, and the induction culture is carried out at 18°C and 200 rpm for 20 hours. The bacteria are collected by centrifugation at 3750 rpm for 15 minutes. The specific implementation method is shown in Example 3.
[0017] In vitro catalytic conversion reaction: The fermented bacteria obtained above were resuspended in kpi buffer and then ultrasonically disrupted to obtain cell lysates of cytochrome P450 enzyme and opt13, respectively. The two were mixed in proportion to obtain a three-component in vitro catalytic system including cytochrome P450 enzyme, reduced protein RHFRed and phosphite dehydrogenase opt13 for efficient NADPH supply. Substrates glycyrrhetinic acid, Na2HPO3·5H2O and NADP were added to the three-component catalytic system. + After reacting at 23° C. for 20 hours, the reaction product is extracted and concentrated, and the content of 7β-hydroxyglycyrrhetinic acid is detected by HPLC, and the activity and (or) selectivity of cytochrome P450 enzyme mutants are screened. The specific implementation method is shown in Example 4.
[0018] The formula of the trace metal salt solution is: 50mM FeCl3, 20mM CaCl2, 10mM MnSO4, 10mM ZnSO4, 2mM CoSO4, 2mM CuCl2, 2mM NiCl2, 2mM Na2MoO4, 2mM H3BO3. The trace metal salt solution is added to the TB culture medium at a ratio of 0.1% v / v.
[0019] The composition of the above-mentioned kpi buffer solution is 14.25g K2HPO4·3H2O and 5.1g KH2PO4 dissolved in 1L distilled water to obtain a phosphate buffer solution with a pH of 7 and a concentration of 0.1M.
[0020] The concentration of the kpi buffer is preferably 0.1 M, and the pH value is preferably 7.0.
[0021] The above cytochrome P450 oxidase and opt13 were added in a ratio of 2:1.
[0022] The present invention also provides a gene encoding the amino acid of the cytochrome P450 enzyme mutant.
[0023] The invention also provides a recombinant plasmid and a recombinant bacterium, which contain the gene.
[0024] The present invention also provides the use of the cytochrome P450 enzyme mutant, gene or recombinant plasmid, and recombinant bacteria in catalyzing glycyrrhetinic acid and / or producing 7β-hydroxyglycyrrhetinic acid.
[0025] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: 1. The present invention uses the amino acid sequence shown in SEQ ID NO.1 as a template (basis), and on the basis of this amino acid sequence, performs mutation modification on the key active sites of the cytochrome P450 enzyme, constructs a mutant library, and screens to obtain a series of mutants with significantly improved catalytic activity and / or selectivity; 2. The cytochrome P450 enzyme mutant provided by the present invention can catalyze glycyrrhetinic acid to generate 7β-hydroxyglycyrrhetinic acid, and has excellent selectivity and high yield. The mutant can be used in the preparation of 7β-hydroxyglycyrrhetinic acid by biological enzyme catalysis of glycyrrhetinic acid, thereby reducing the production cost of 7β-hydroxyglycyrrhetinic acid, and can generate 7β-hydroxyglycyrrhetinic acid with high activity and high regioselectivity, achieving g-scale preparation, which is conducive to simplifying the separation operation in the process, is easy to implement in engineering, and provides a more effective tool for the structural modification of glycyrrhetinic acid. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 HPLC charts of 7β-hydroxyglycyrrhetinic acid and 7β,15α-dihydroxyglycyrrhetinic acid produced by glycyrrhetinic acid catalyzed by the parent or variant. DETAILED DESCRIPTION
[0027] The technical solution of the present invention is further described below in conjunction with the accompanying drawings.
[0028] Example 1 Synthesis and recombinant expression of template pET28a-ApPT-RHFRed
[0029] The cytochrome P450 enzyme gene CYP161H12 (amino acid sequence UniProt No. A0A1H5RFX8, hereinafter referred to as: ApPT) was used as a parent template for synthesis and recombinant expression of the template pET28a-ApPT-RHFRed; the nucleotide sequence of the parent template ApPT is shown in SEQ ID NO.2, and the amino acid sequence is shown in SEQ ID NO.1; the ApPT with the nucleotide sequence shown in SEQ ID NO.2 was inserted into the pET28a-RHFRed plasmid whose restriction endonuclease cutting sites were NdeI and BamHI, respectively, and the recombinant vector pET28a-ApPT-RHFRed was directly obtained by synthesis by General Biotechnology (Anhui) Co., Ltd. Among them, the synthesis process of pET28a-RHFRed is as follows: RHFRed is inserted into pET28a with restriction endonuclease cutting sites of BamHI and XhoI respectively according to the amino acid sequence reported in the literature in 2020, and synthesized by General Bio (Anhui) Co., Ltd. to obtain the vector pET28a-RHFRed. The amino acid sequence of RHFRed is SEQ ID NO.3, and the gene sequence is SEQ ID NO.4. The pET28a-ApPT-RHFRed recombinant plasmid was transformed into E.coli BL21 competent cells by heat shock method, and positive transformants were screened on LB solid medium (containing 50μg / mL kanamycin); a single clone was picked into 5mL of sterile LB liquid medium (containing 50μg / mL kanamycin), and cultured at 37°C and 220rpm for 10h to obtain the pET28a-ApPT-RHFRed recombinant bacterial solution.
[0030] The above recombinant bacterial solution was added to 50 mL sterilized TB medium at a 0.4% inoculum, and kanamycin at a final concentration of 50 μg / mL and trace metal salt solution (composition includes 50 mM FeCl3, 20 mM CaCl2, 10 mM MnSO4, 10 mM ZnSO4, 2 mM CoSO4, 2 mM CuCl2, 2 mM NiCl2, 2 mM Na2MoO4, 2 mM H3BO3) at a final concentration of 1 mL / L were added thereto. Culture was carried out at 37°C and 220 rpm until OD 600 The value was 0.6-0.8. After cooling in an ice water bath for 20 min, add a final concentration of 0.1 mM isopropyl-β-D-thiogalactoside (IPTG) solution and a final concentration of 0.5 mM 5-aminolevulinic acid hydrochloride (5-ALA) solution to induce the bacteria to express pET28a-ApPT-RHFRed fusion protein, and induce culture at 18°C and 200 rpm for 20 h. Collect the bacteria by centrifugation at 3750 rpm for 15 min.
[0031] Example 2 Construction of cytochrome P450 enzyme mutants
[0032] Based on the molecular docking structure of ApPT and substrate glycyrrhetinic acid, four residues T291, T288, S289, and G290 adjacent to the catalytic residues of ApPT were mutated to construct mutants. Using pET28a-ApPT-RHFRed plasmid as a template, any of the following amino acid mutations occurred: T291I, T291V, T291S, T291F, T291I, T291L, T291C, T288A, T288V, T291I-T288A, T291I-T288G, T291I-T288A-G290E, T291I-T288G-S289Q, T291I-T288A-S289Q-G290E, T291I-T288G-S289Q-G290E. When there are multiple mutation sites, it needs to be done in batches, with only one site mutated each time.
[0033] Each mutation included the following steps: using pET28a-ApPT-RHFRed plasmid as a template, designing mutation primers, and placing the base to be mutated in the middle of the primers; the first PCR amplification system: 2×Phanta Max Buffer 25μL, 10mM dNTPs1μL, 50μM upstream and downstream primers 5μL each, 100ng / μL DNA template 1μL, high-fidelity polymerase (Phanta Max Super-Fidelity DNA Polymerase) 1μL, DMSO 2.5μL, ddH2O to 50μL; the first PCR reaction conditions were: 95℃ pre-denaturation for 5min, 95℃ denaturation for 10s, 72℃ annealing for 15s, 72℃ extension for 1min, 30 cycles of reaction, and finally 72℃ extension for 10min. Among them, the upstream primer for cloning the first half of the mutation site gene is ApPT-F, and the downstream primer is the corresponding site-R; the upstream primer for cloning the second half of the mutation site gene is the corresponding site-F, and the downstream primer is ApPT-R. The genes cloned by the first PCR were subjected to the second PCR, and the second PCR amplification system was: 2×Phanta Max Buffer 25μL, 10mM dNTPs 1μL, 50μM upstream and downstream primers 5μL each, DNA template was 20ng of the first half of the mutation site gene and the second half of the mutation site gene, high-fidelity polymerase (Phanta Max Super-Fidelity DNA Polymerase) 1μL, DMSO 2.5μL, ddH2O supplemented to 50μL; the second PCR reaction conditions were: 95℃ pre-denaturation for 5min, 95℃ denaturation for 10s, 63℃ annealing for 15s, 72℃ extension for 1min, reaction for 30 cycles, and finally 72℃ extension for 10min. Among them, the upstream primer of the second PCR is ApPT-F, and the downstream primer is ApPT-R.
[0034] The sequences of the upstream and downstream mutation primers used in this example are shown in Table 1 below:
[0035] Table 1 Sequences of upstream and downstream mutation primers
[0036]
[0037]
[0038] The plasmid pET28a-RHFRed was digested with NdeI and BamHI, and the digestion system was: 100ng / μL plasmid pET28a-RHFRed 1μg, 10×QuickCut Buffer 2μL, NdeI 1μL, BamHI 1μL, ddH2O supplemented to 20μL, and the reaction conditions were 37℃1.5h. The linearized vector and the gene amplified by PCR were homologously recombined using the C112 homologous recombination kit (Nanjing Novogene Biotechnology Co., Ltd.), transformed into E.coli DH5α competent cells, and positive transformants were screened on LB solid medium (containing 50μg / mL kanamycin); monoclonal colonies were picked and cultured in 5mL LB liquid medium containing 50μg / mL kanamycin, and then sequenced. The sequencing results were compared with the gene sequence of wild-type ApPT using SnapGene software, and plasmids were extracted from the strains with correct sequencing to obtain the recombinant plasmid of cytochrome P450 enzyme mutants. The recombinant plasmid of cytochrome P450 enzyme mutants was transformed into E.coli BL21 competent cells using the heat shock method, and positive transformants were screened on LB solid medium (containing 50μg / mL kanamycin); single clones were picked into 5mL of sterilized LB liquid medium (containing 50μg / mL kanamycin), and cultured at 37°C and 220rpm for 10h to obtain the recombinant bacterial liquid of cytochrome P450 enzyme mutants. Among them, the expression of cytochrome P450 enzyme mutants in E. coli is consistent with the expression method of the above template.
[0039] Example 3 Construction and recombinant expression of phosphite dehydrogenase pRSFDuet-opt13
[0040] The opt13 gene (the article disclosing the gene: Further Improvement of PhosphiteDehydrogenase Thermostability by Saturation Mutagenesis, DOI 10.1002 / bit.21546) was used as a template for synthesis and recombinant expression of plasmid pRSFDuet-opt13. The opt13 gene was directly synthesized by General Biotechnology (Anhui) Co., Ltd., and then primers were designed and PCR amplified to amplify the gene. PCR amplification system: 2×PhantaMax Buffer 25μL, 10mM dNTPs 1μL, 50μM upstream and downstream primers 5μL each, 100ng / μL DNA template 1μL, high-fidelity polymerase (Phanta Max Super-Fidelity DNA Polymerase) 1μL, DMSO 2.5μL, ddH2O to 50μL; PCR reaction conditions: 95℃ pre-denaturation for 5min, 95℃ denaturation for 10s, 72℃ annealing for 15s, 72℃ extension for 1min, reaction for 30 cycles, and finally extension at 72℃ for 10min.
[0041] Among them, the sequences of the upstream and downstream primers are shown in Table 2 below:
[0042] Table 2 Sequences of upstream and downstream primers of opt13
[0043]
[0044] The plasmid pRSFDuet purchased from General Biotechnology (Anhui) Co., Ltd. was digested with PstI and HindIII. The digestion system was: 100ng / μL plasmid pRSFDuet 1μg, 10×QuickCut Buffer 2μL, PstI 1μL, HindIII 1μL, ddH2O supplemented to 20μL, and the reaction conditions were 37℃1.5h. The pRSFDuet vector linearized by enzyme digestion and the gene amplified by PCR were homologously recombined using the C112 homologous recombination kit (Nanjing Novogene Biotechnology Co., Ltd.), transformed into E.coli DH5α competent cells, and positive transformants were screened on LB solid medium (containing 50μg / mL kanamycin); monoclonal colonies were picked and cultured in 5mL LB liquid medium containing 50μg / mL kanamycin, and then sequenced. The plasmid was extracted from the correctly sequenced strain, and the cytochrome P450 enzyme mutant recombinant plasmid was transformed into E. coli BL21 competent cells using the heat shock method. Positive transformants were screened on LB solid medium (containing 50 μg / mL kanamycin); a single clone was picked and transferred to 5 mL of sterile LB liquid medium (containing 50 μg / mL kanamycin), and cultured at 37°C, 220 rpm for 10 h to obtain the pRSFDuet-opt13 recombinant bacterial solution.
[0045] Add the above recombinant bacterial solution to 50 ml sterilized TB medium at a 0.4% inoculum volume, and add kanamycin at a final concentration of 50 μg / mL. Cultivate at 37°C, 220 rpm until OD 600 The value was 0.6-0.8. After cooling in an ice water bath for 20 minutes, 0.1 mM isopropyl-β-D-thiogalactoside (IPTG) was added to induce the cells to express protein opt13, and the cells were induced and cultured at 18°C and 200 rpm for 20 hours. The cells were collected by centrifugation at 3750 rpm for 15 minutes.
[0046] Example 4 Activity and / or selectivity screening of cytochrome P450 enzyme mutants
[0047] In this example, glycyrrhetinic acid was used as a substrate to determine the catalytic activity and selectivity of the cytochrome P450 enzyme mutant compared to the parent template P450;
[0048] The parental template P450, cytochrome P450 enzyme mutant and opt13 bacteria were resuspended in 0.1 M, pH = 7.0 kpi buffer to OD 600 = 30 and then ultrasonically disrupted to obtain the parent template P450, cytochrome P450 enzyme mutant and cell lysates of opt13, wherein cytochrome P450 enzyme is the reaction catalyst.
[0049] 1.33 mL of the parent template P450, 1.33 mL of the cell lysate of the cytochrome P450 enzyme mutant and 0.66 mL of the opt13 cell lysate were mixed and added to a 48-deep-well plate, and the substrates glycyrrhetinic acid (4 mM, 1.0 equiv.), NaNADP (0.5 equiv.) and Na2HPO3·5H2O (50 equiv.) pre-dissolved in 5% (v / v) DMSO were added thereto. After reacting at 23°C and 220rpm for 20h, 2mL of ethyl acetate was added to fully extract the reaction solution, and high-speed centrifugation was performed at 13000rpm for 10min. 1mL of the organic phase was taken into a 1.5mL EP tube, dried with nitrogen, and 1mL of chromatographic methanol was added and filtered with a microporous filter membrane (0.22μm). The filtrate was placed in a clean liquid analysis sample bottle and the content was detected by HPLC. The detection conditions were: 20% acetonitrile-100% acetonitrile gradient elution for 5min, 100% acetonitrile for 5min, flow rate of 0.8ml / min, and detection wavelength of 254nm. The obtained effective mutants are T291A, T291V, T291S, T291F, T291I, T291L, T291C, T288A, T288V, T291I-T288A, T291I-T288G, T291I-T288G-S289Q, T291I-T288A-G290E, T291I-T288G-S289Q-G290E and T291I-T288A-S289Q-G290E. The HPLC charts of the products 7β-hydroxyglycyrrhetinic acid and 7β,15α-dihydroxyglycyrrhetinic acid generated by glycyrrhetinic acid catalyzed by the parent or partial variants are shown in Figure 1 The activity and selectivity test results of the mutants are shown in Table 3 below:
[0050] Table 3 Activity and selectivity test results of mutants
[0051]
[0052]
[0053] Note: The test results in Table 3 were obtained after three parallel reactions under the same reaction conditions. The selectivity is defined as: 7β-hydroxyglycyrrhetinic acid / (7β-hydroxyglycyrrhetinic acid+7β,15α-dihydroxyglycyrrhetinic acid)×100%; the reaction route of cytochrome P450 enzyme mutant catalyzing glycyrrhetinic acid 1 to generate 7β-hydroxyglycyrrhetinic acid 1a can be referred to:
[0054]
[0055] Among them, mutant T291A: the 291st amino acid of the parent (ApPT) was mutated from T to A; mutant T291V: the 291st amino acid of the parent (ApPT) was mutated from T to V; mutant T291S: the 291st amino acid of the parent (ApPT) was mutated from T to S; mutant T291F: the 291st amino acid of the parent (ApPT) was mutated from T to F; mutant T291I: the 291st amino acid of the parent (ApPT) was mutated from T to F. T) the 291st amino acid of the parent (ApPT) was mutated from T to I; mutant T291L: the 291st amino acid of the parent (ApPT) was mutated from T to L; mutant T291C: the 291st amino acid of the parent (ApPT) was mutated from T to C; mutant T288A: the 288th amino acid of the parent (ApPT) was mutated from T to A; mutant T288V: the 288th amino acid of the parent (ApPT) was mutated from T to V; mutant T291I-T288A: The 288th amino acid of mutant T291I is mutated from T to A; mutant T291I-T288G: The 288th amino acid of mutant T291I is mutated from T to G; mutant T291I-T288G-S289Q: The 289th amino acid of mutant T291I-T288G is mutated from S to Q; mutant T291I-T288A-G290E: The mutant The 290th amino acid of T291I-T288A was mutated from G to E; mutant T291I-T288G-S289Q-G290E: the 290th amino acid of mutant T291I-T288G-S289Q was mutated from G to E; mutant T291I-T288A-S289Q-G290E: the 289th amino acid of mutant T291I-T288A-G290E was mutated from S to Q.
[0056] According to the test results in Table 3, in this example, the key active sites were mutated based on the template (P450) to obtain mutants with significantly improved activity and / or selectivity in catalyzing the 7β-hydroxylation reaction of glycyrrhetinic acid.
[0057] The mutant provided in this embodiment can improve the selectivity of glycyrrhetinic acid to generate 7β-hydroxyglycyrrhetinic acid alone, can improve the activity of glycyrrhetinic acid to generate 7β-hydroxyglycyrrhetinic acid alone, or can improve the selectivity and yield of glycyrrhetinic acid to generate 7β-hydroxyglycyrrhetinic acid at the same time. Thus, the problem of poor selectivity of cytochrome P450 enzymes (such as template ApPT) in the prior art is overcome.
[0058] Further combining Table 3 and Figure 1It can be seen that the combined mutation T291I+T288G+S289Q+G290E not only exhibits better catalytic activity, but also significantly improves selectivity, with the yield increasing from 74.56% to 85.12% and the selectivity increasing from 67.72% to >99%.
[0059] Example 5 Large-scale preparation of enzyme-catalyzed oxidation products
[0060] Based on the test results of Example 4, this example uses the mutant T291I+T288G+S289Q+G290E as an exemplary mutant (the amino acid sequence is shown in SEQ ID NO.5, and the nucleotide sequence is shown in SEQ ID NO.6) to prepare the enzyme-catalyzed oxidation product 7β-hydroxyglycyrrhetinic acid on a large scale.
[0061] The mutant T291I+T288G+S289Q+G290E obtained in Example 4 was fermented and induced in 2L TB medium, and opt13 was fermented and induced in 1L TB medium to obtain the mutant T291I+T288G+S289Q+G290E and opt13 fermentation cells, respectively. The expression method was the same as in Example 1. The cells were resuspended in 0.1M, pH=7.0kpi buffer and then ultrasonically disrupted to obtain the mutants.
[0062] T291I+T288G+S289Q+G290E and opt13 cell lysates.
[0063] The cell lysate of T291I+T288G+S289Q+G290E cytochrome P450 enzyme mutant and opt13 cell lysate were mixed, and the substrate glycyrrhetinic acid (1 g, 1.0 equiv.), NaNADP (0.5 equiv.) and Na2HPO3·5H2O (50 equiv.) pre-dissolved in 5% (v / v) DMSO were added thereto. After reacting at 23°C and 220 rpm for 20 h, the reaction solution was extracted three times with an equal volume of ethyl acetate, and the organic solvents were finally combined and dried by rotary evaporation to obtain the oxidation product 7β-hydroxyglycyrrhetinic acid with a yield of 88.93%.
Claims
1. A cytochrome P450 enzyme mutant, characterized in that: The mutation site of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT shown in SEQ ID NO.1 is any one or several of positions 288-291; the amino acid at position 288 mutates from threonine to alanine, valine or glycine; the amino acid at position 289 mutates from serine to glutamine; the amino acid at position 290 mutates from glycine to glutamate; the amino acid at position 291 mutates from threonine to alanine, valine, serine, phenylalanine, isoleucine, leucine or cysteine.
2. The cytochrome P450 enzyme mutant according to claim 1, characterized in that: The mutation site of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT shown in SEQ ID NO.1 is position 291; the amino acid at position 291 mutates from threonine to alanine, valine, serine, phenylalanine, isoleucine, leucine or cysteine.
3. The cytochrome P450 enzyme mutant according to claim 1, characterized in that: The mutation site of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT shown in SEQ ID NO.1 is position 288; the amino acid at position 288 is mutated from threonine to alanine or valine.
4. The cytochrome P450 enzyme mutant according to claim 1, characterized in that: The mutation sites of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT shown in SEQ ID NO.1 are positions 291 and 288; the amino acid at position 291 mutates from threonine to isoleucine; and the amino acid at position 288 mutates from threonine to alanine or glycine.
5. The cytochrome P450 enzyme mutant according to claim 1, characterized in that: The mutation sites of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT shown in SEQ ID NO.1 are position 291 and position 288-289; the amino acid at position 291 mutates from threonine to isoleucine; the amino acid at position 288 mutates from threonine to glycine; and the amino acid at position 289 mutates from serine to glutamine.
6. The cytochrome P450 enzyme mutant according to claim 1, characterized in that: The mutation sites of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT as shown in SEQ ID NO.1 are positions 291, 288 and 290; the amino acid at position 291 mutates from threonine to isoleucine; the amino acid at position 288 mutates from threonine to alanine; and the amino acid at position 290 mutates from glycine to glutamate.
7. The cytochrome P450 enzyme mutant according to claim 1, characterized in that: The mutation sites of the cytochrome P450 enzyme mutant relative to the amino acid sequence of ApPT shown in SEQ ID NO.1 are positions 288-291; the amino acid at position 291 mutates from threonine to isoleucine; the amino acid at position 288 mutates from threonine to alanine or glycine; the amino acid at position 289 mutates from serine to glutamine; and the amino acid at position 290 mutates from glycine to glutamate.
8. A gene encoding the amino acid of the cytochrome P450 enzyme mutant according to any one of claims 1 to 7.
9. A recombinant plasmid or a recombinant bacterium, characterized in that: It comprises the gene according to claim 8.
10. Use of the cytochrome P450 enzyme mutant according to any one of claims 1 to 7, the gene according to claim 8, or the recombinant plasmid or recombinant bacteria according to claim 9 in catalyzing glycyrrhetinic acid and / or producing 7β-hydroxyglycyrrhetinic acid.
Citation Information
Cited By
Heme iron cytochrome P450 enzyme mutant with improved enzyme electrocatalysis rate
CN120989024A
B ring diversified modified pentacyclic triterpene derivative as well as preparation method and application thereof
CN122628120A
